{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-001488","form_type":"8-K","ticker":"PRPH","cik":"0000868278","company_name":"ProPhase Labs, Inc.","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.560271+00:00","generated_at":"2026-05-24T02:42:55.607154+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"ProPhase Labs reports FY2024 net loss of $53.4M; revenue down 81% to $6.8M","bullets":["Net revenue fell 80.6% to $6.8M from $35.0M, driven by near-zero COVID-19 testing volumes.","Net loss widened to $53.4M ($2.61/share) vs $16.8M ($0.98/share) in FY2023; gross loss of $0.2M.","Manufacturing division sold for ~$23M in Jan 2025; employee count reduced from 96 to 28.","Cash and equivalents $0.7M at Dec 31, 2024, down from $1.6M; working capital deficit of $1.5M.","Company plans cash-pay launch of BE-Smart esophageal test; evaluating sale of Nebula Genomics."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-001488","json":"https://secwatch.observer/filing/0001641172-25-001488.json","markdown":"https://secwatch.observer/filing/0001641172-25-001488.md","text":"https://secwatch.observer/filing/0001641172-25-001488.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/868278/000164117225001488/0001641172-25-001488-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/868278/000164117225001488/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T02:42:55.607154+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}